Enteric bile acid–protein co‑aggregation as a compensatory proteostatic response to age‑related ASBT upregulation

Brett Christiansen· Mar 24, 2026

Mechanism: Age-related ASBT upregulation drives toxic CPBA-protein co-aggregation in enterocytes, which initially sequesters toxins but eventually leads to soluble toxic complexes escaping to the brain. Readout: Readout: ASBT inhibition combined with young microbiota transplantation decreases aggregates, increases autophagy flux, and significantly improves cognition.

{
  "title": "Enteric bile acid–protein co‑aggregation as a compensatory proteostatic response to age‑related ASBT upregulation",
  "body": "# Hypothesis\nAge‑dependent upregulation of ileal ASBT drives luminal accumulation of conjugated primary bile acids (CPBAs) that nucleate the formation of insoluble bile acid–protein co‑aggregates within enterocytes. These co‑aggregates act as a sequestration mechanism that temporarily shields systemic proteostasis from CPBA‑induced toxicity. When the sequestration capacity is exceeded, soluble CPBA‑protein species leak into the portal circulation, contributing to hippocampal synapse loss and cognitive decline. Therefore, reducing ASBT expression will decrease co‑aggregate formation but increase the pool of soluble cytotoxic CPBA‑protein complexes, worsening neurodegeneration unless paired with microbiota‑mediated conversion to secondary bile acids.\n\n## Mechanistic Rationale\n- **ASBT elevation with age** raises ileal CPBA reabsorption despite reduced hepatic synthesis, elevating serum taurocholic acid and other CPBAs [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11148718/)] [[2](https://pubmed.ncbi.nlm.nih.gov/38697101/)].\n- CPBAs are amphipathic and can bind exposed hydrophobic patches on misfolded proteins, promoting nucleation of ordered aggregates. In youth, FXR‑FGF15/19 signaling limits ASBT activity and promotes conversion to secondary bile acids that possess chemical chaperone properties [[3](https://pubmed.ncbi.nlm.nih.gov/35026209/)] [[4](https://www.tandfonline.com/doi/full/10.1080/19490976.2020.1763770)].\n- Age‑associated microbiota remodeling diminishes 7α‑dehydroxylation and deconjugation, shifting the bile acid pool toward neurotoxic CPBAs that favor aggregation [[4](https://www.tandfonline.com/doi/full/10.1080/19490976.2020.1763770)].\n- Enterocytes may cope by sequestering CPBA‑protein complexes into insoluble granules, analogous to the proteostasis strategy of converting dangerous oligomers into inert amyloid‑like deposits (seed idea). This reduces free CPBA concentrations that could otherwise impair hepatic autophagy and synaptic integrity [[5](https://doi.org/10.1111/acel.12708)].\n- When granule capacity is surpassed, soluble CPBA‑protein species escape, reaching the brain via circulation and inducing synapse loss [[2](https://pubmed.ncbi.nlm.nih.gov/38697101/)].\n\n## Testable Predictions\n1. **Co‑aggregate detection** – Immuno‑electron microscopy of ileal enterocytes from young vs. aged mice will reveal CPBA‑positive, protein‑positive insoluble granules that increase with age.\n2. **ASBT inhibition effect** – Genetic knockdown or pharmacological blockade of ASBT (e.g., with ASBTi) will reduce granule burden but increase soluble CPBA‑protein complexes in portal plasma, exacerbating hippocampal markers of inflammation and synapse loss unless secondary bile acid supplementation is provided.\n3. **Microbiota rescue** – Transplanting microbiota from young donors into aged, ASBT‑upregulated mice will restore 7α‑dehydroxylation, lower CPBA levels, decrease granule formation, and improve cognition, even when ASBT remains elevated.\n4. **Proteostasis read‑out** – Levels of ubiquitin‑positive aggregates and autophagic flux (LC3‑II/I ratio) in hepatocytes and hippocampi will correlate inversely with intestinal granule load.\n\n## Potential Experimental Approach\n- **Mouse models**: aged wild‑type, intestinal‑specific ASBT knockout, and ASBT‑overexpressing lines; treat subsets with cholestyramine, ASBT inhibitor, or secondary bile acid (e.g., deoxycholic acid) supplementation.\n- **Readouts**: quantify ileal granule formation via CPBA and p62 co‑staining; measure portal CPBA‑protein complexes by size‑exclusion chromatography coupled to mass spectrometry; assess hippocampal synapse markers (synaptophysin, PSD‑95) and cognitive performance (Morris water maze).\n- **Microbiota manipulations**: fecal microbiota transplantation from young donors; metagenomic sequencing to confirm restoration of bile acid‑deconjugating enzymes.\n\nIf predictions hold, the data would support a model where ileal ASBT‑driven bile acid sequestration is a maladaptive yet initially protective attempt to manage proteotoxic stress, reframing therapeutic focus from simple ASBT inhibition to coordinated restoration of microbial bile acid metabolism alongside controlled modulation of transporter activity."
}

{ "title": "Enteric bile acid–protein co‑aggregation as a compensatory proteostatic response to age‑related ASBT upregulation", "body": "# Hypothesis\nAge‑dependent upregulation of ileal ASBT drives luminal accumulation of conjugated primary bile acids (CPBAs) that nucleate the formation of insoluble bile acid–protein co‑aggregates within enterocytes. These co‑aggregates act as a sequestration mechanism that temporarily shields systemic proteostasis from CPBA‑induced toxicity. When the sequestration capacity is exceeded, soluble CPBA‑protein species leak into the portal circulation, contributing to hippocampal synapse loss and cognitive decline. Therefore, reducing ASBT expression will decrease co‑aggregate formation but increase the pool of soluble cytotoxic CPBA‑protein complexes, worsening neurodegeneration unless paired with microbiota‑mediated conversion to secondary bile acids.\n\n## Mechanistic Rationale\n- **ASBT elevation with age** raises ileal CPBA reabsorption despite reduced hepatic synthesis, elevating serum taurocholic acid and other CPBAs [[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11148718/)] [[2](https://pubmed.ncbi.nlm.nih.gov/38697101/)].\n- CPBAs are amphipathic and can bind exposed hydrophobic patches on misfolded proteins, promoting nucleation of ordered aggregates. In youth, FXR‑FGF15/19 signaling limits ASBT activity and promotes conversion to secondary bile acids that possess chemical chaperone properties [[3](https://pubmed.ncbi.nlm.nih.gov/35026209/)] [[4](https://www.tandfonline.com/doi/full/10.1080/19490976.2020.1763770)].\n- Age‑associated microbiota remodeling diminishes 7α‑dehydroxylation and deconjugation, shifting the bile acid pool toward neurotoxic CPBAs that favor aggregation [[4](https://www.tandfonline.com/doi/full/10.1080/19490976.2020.1763770)].\n- Enterocytes may cope by sequestering CPBA‑protein complexes into insoluble granules, analogous to the proteostasis strategy of converting dangerous oligomers into inert amyloid‑like deposits (seed idea). This reduces free CPBA concentrations that could otherwise impair hepatic autophagy and synaptic integrity [[5](https://doi.org/10.1111/acel.12708)].\n- When granule capacity is surpassed, soluble CPBA‑protein species escape, reaching the brain via circulation and inducing synapse loss [[2](https://pubmed.ncbi.nlm.nih.gov/38697101/)].\n\n## Testable Predictions\n1. **Co‑aggregate detection** – Immuno‑electron microscopy of ileal enterocytes from young vs. aged mice will reveal CPBA‑positive, protein‑positive insoluble granules that increase with age.\n2. **ASBT inhibition effect** – Genetic knockdown or pharmacological blockade of ASBT (e.g., with ASBTi) will reduce granule burden but increase soluble CPBA‑protein complexes in portal plasma, exacerbating hippocampal markers of inflammation and synapse loss unless secondary bile acid supplementation is provided.\n3. **Microbiota rescue** – Transplanting microbiota from young donors into aged, ASBT‑upregulated mice will restore 7α‑dehydroxylation, lower CPBA levels, decrease granule formation, and improve cognition, even when ASBT remains elevated.\n4. **Proteostasis read‑out** – Levels of ubiquitin‑positive aggregates and autophagic flux (LC3‑II/I ratio) in hepatocytes and hippocampi will correlate inversely with intestinal granule load.\n\n## Potential Experimental Approach\n- **Mouse models**: aged wild‑type, intestinal‑specific ASBT knockout, and ASBT‑overexpressing lines; treat subsets with cholestyramine, ASBT inhibitor, or secondary bile acid (e.g., deoxycholic acid) supplementation.\n- **Readouts**: quantify ileal granule formation via CPBA and p62 co‑staining; measure portal CPBA‑protein complexes by size‑exclusion chromatography coupled to mass spectrometry; assess hippocampal synapse markers (synaptophysin, PSD‑95) and cognitive performance (Morris water maze).\n- **Microbiota manipulations**: fecal microbiota transplantation from young donors; metagenomic sequencing to confirm restoration of bile acid‑deconjugating enzymes.\n\nIf predictions hold, the data would support a model where ileal ASBT‑driven bile acid sequestration is a maladaptive yet initially protective attempt to manage proteotoxic stress, reframing therapeutic focus from simple ASBT inhibition to coordinated restoration of microbial bile acid metabolism alongside controlled modulation of transporter activity." }